Surmodics (SRDX) Projected to Post Quarterly Earnings on Wednesday

Surmodics (NASDAQ:SRDX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $32.23 million for the quarter. Surmodics has set its FY 2025 guidance at -0.620--0.420 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The firm had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. On average, analysts expect Surmodics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Surmodics Stock Performance

SRDX traded down $0.22 during trading on Friday, reaching $27.64. 79,617 shares of the company's stock were exchanged, compared to its average volume of 278,216. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. Surmodics has a 1 year low of $26.00 and a 1 year high of $42.44. The company's fifty day simple moving average is $29.43 and its 200-day simple moving average is $34.89. The stock has a market capitalization of $395.14 million, a P/E ratio of -27.37 and a beta of 1.30.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. StockNews.com initiated coverage on Surmodics in a research report on Monday, February 3rd. They set a "hold" rating on the stock. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a research report on Friday, March 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $43.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).